ArticleNeurology2024
Association of Glycemic Variability With Imaging Markers of Vascular Burden, β-Amyloid, Brain Atrophy, and Cognitive Impairment.
Erratum issuedOpen access · greenAbstract read
In one paragraph
Article in Neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 9 papers.
0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.9field-weighted citation impact, top 8% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 13 citations in OpenAlex.
- Association Between Visit-to-Visit Glucose Variability and Brain Morphology and Cognitive Function in Type 2 Diabetes.The Journal of clinical endocrinology and metabolism · 2025Article
- Twelve-year nationwide cohort study identifying risk factors for conversion from mild cognitive impairment to Alzheimer's disease.Scientific reports · 2025Article
- Association between cerebral lesions and the severity of diabetic cardiovascular disease, retinopathy, and nephropathy-new lessons to learn from neuroimaging.Journal of endocrinological investigation · 2025Review
- Comprehensive Clinical and Behavioral Characteristics of Mild Cognitive Impairment According to Amyloid Positivity: A Large Multi-Center Korean Cohort.Dementia and neurocognitive disorders · 2025Article
- Machine learning reveals distinct neuroanatomical signatures of cardiovascular and metabolic diseases in cognitively unimpaired individuals.Nature communications · 2025Article
- Plasma Alzheimer's disease biomarker variability: Amyloid-independent and amyloid-dependent factors.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- HbAAlzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Corrections to Received Date Information.Neurology · 2024Article
- Association of Glycemic Variability With Imaging Markers of Vascular Burden, β-Amyloid, Brain Atrophy, and Cognitive Impairment.Neurology · 2024Article
Corrections and comments
- Erratum issued
- Erratum issued
Authors and funding
12 authors at 1 institution in 2 countries.
Hyemin JangFrom the Alzheimer's Disease Convergence Research Center (H.J., S.A., Y.P., S.-J.K., B.K.C., J.H.K., H.J.K., D.L.N., J.P.K., S.W.S.), Samsung Medical Center; Department of Digital Health (H.J., S.L., K.K., S.W.S.), Samsung Advanced Institute for Health Sciences & Technology, Sungkyunkwan University; Department of Neurology (H.J., H.J.K., J.P.K., S.W.S.), Samsung Medical Center, Sungkyunkwan University School of Medicine; Neuroscience Center (H.J., H.J.K., J.P.K., S.W.S.), Samsung Medical Center; Happymind Clinic (D.L.N.); Biomedical Statistics Center (K.K.), Research Institute for Future Medicine, Samsung Medical Center; and Department of Data Convergence and Future Medicine (K.K.), Sungkyunkwan University School of Medicine, Seoul, Korea. Dr. Jang is currently at the Department of Neurology, Seoul National University Hospital, Korea.ORCID 0000-0003-3152-1274
Sungjoo LeeFrom the Alzheimer's Disease Convergence Research Center (H.J., S.A., Y.P., S.-J.K., B.K.C., J.H.K., H.J.K., D.L.N., J.P.K., S.W.S.), Samsung Medical Center; Department of Digital Health (H.J., S.L., K.K., S.W.S.), Samsung Advanced Institute for Health Sciences & Technology, Sungkyunkwan University; Department of Neurology (H.J., H.J.K., J.P.K., S.W.S.), Samsung Medical Center, Sungkyunkwan University School of Medicine; Neuroscience Center (H.J., H.J.K., J.P.K., S.W.S.), Samsung Medical Center; Happymind Clinic (D.L.N.); Biomedical Statistics Center (K.K.), Research Institute for Future Medicine, Samsung Medical Center; and Department of Data Convergence and Future Medicine (K.K.), Sungkyunkwan University School of Medicine, Seoul, Korea. Dr. Jang is currently at the Department of Neurology, Seoul National University Hospital, Korea.
Sungsik AnFrom the Alzheimer's Disease Convergence Research Center (H.J., S.A., Y.P., S.-J.K., B.K.C., J.H.K., H.J.K., D.L.N., J.P.K., S.W.S.), Samsung Medical Center; Department of Digital Health (H.J., S.L., K.K., S.W.S.), Samsung Advanced Institute for Health Sciences & Technology, Sungkyunkwan University; Department of Neurology (H.J., H.J.K., J.P.K., S.W.S.), Samsung Medical Center, Sungkyunkwan University School of Medicine; Neuroscience Center (H.J., H.J.K., J.P.K., S.W.S.), Samsung Medical Center; Happymind Clinic (D.L.N.); Biomedical Statistics Center (K.K.), Research Institute for Future Medicine, Samsung Medical Center; and Department of Data Convergence and Future Medicine (K.K.), Sungkyunkwan University School of Medicine, Seoul, Korea. Dr. Jang is currently at the Department of Neurology, Seoul National University Hospital, Korea.
Yuhyun ParkFrom the Alzheimer's Disease Convergence Research Center (H.J., S.A., Y.P., S.-J.K., B.K.C., J.H.K., H.J.K., D.L.N., J.P.K., S.W.S.), Samsung Medical Center; Department of Digital Health (H.J., S.L., K.K., S.W.S.), Samsung Advanced Institute for Health Sciences & Technology, Sungkyunkwan University; Department of Neurology (H.J., H.J.K., J.P.K., S.W.S.), Samsung Medical Center, Sungkyunkwan University School of Medicine; Neuroscience Center (H.J., H.J.K., J.P.K., S.W.S.), Samsung Medical Center; Happymind Clinic (D.L.N.); Biomedical Statistics Center (K.K.), Research Institute for Future Medicine, Samsung Medical Center; and Department of Data Convergence and Future Medicine (K.K.), Sungkyunkwan University School of Medicine, Seoul, Korea. Dr. Jang is currently at the Department of Neurology, Seoul National University Hospital, Korea.
Soo-Jong KimFrom the Alzheimer's Disease Convergence Research Center (H.J., S.A., Y.P., S.-J.K., B.K.C., J.H.K., H.J.K., D.L.N., J.P.K., S.W.S.), Samsung Medical Center; Department of Digital Health (H.J., S.L., K.K., S.W.S.), Samsung Advanced Institute for Health Sciences & Technology, Sungkyunkwan University; Department of Neurology (H.J., H.J.K., J.P.K., S.W.S.), Samsung Medical Center, Sungkyunkwan University School of Medicine; Neuroscience Center (H.J., H.J.K., J.P.K., S.W.S.), Samsung Medical Center; Happymind Clinic (D.L.N.); Biomedical Statistics Center (K.K.), Research Institute for Future Medicine, Samsung Medical Center; and Department of Data Convergence and Future Medicine (K.K.), Sungkyunkwan University School of Medicine, Seoul, Korea. Dr. Jang is currently at the Department of Neurology, Seoul National University Hospital, Korea.
Bo Kyoung CheonFrom the Alzheimer's Disease Convergence Research Center (H.J., S.A., Y.P., S.-J.K., B.K.C., J.H.K., H.J.K., D.L.N., J.P.K., S.W.S.), Samsung Medical Center; Department of Digital Health (H.J., S.L., K.K., S.W.S.), Samsung Advanced Institute for Health Sciences & Technology, Sungkyunkwan University; Department of Neurology (H.J., H.J.K., J.P.K., S.W.S.), Samsung Medical Center, Sungkyunkwan University School of Medicine; Neuroscience Center (H.J., H.J.K., J.P.K., S.W.S.), Samsung Medical Center; Happymind Clinic (D.L.N.); Biomedical Statistics Center (K.K.), Research Institute for Future Medicine, Samsung Medical Center; and Department of Data Convergence and Future Medicine (K.K.), Sungkyunkwan University School of Medicine, Seoul, Korea. Dr. Jang is currently at the Department of Neurology, Seoul National University Hospital, Korea.
Ji Hyun KimFrom the Alzheimer's Disease Convergence Research Center (H.J., S.A., Y.P., S.-J.K., B.K.C., J.H.K., H.J.K., D.L.N., J.P.K., S.W.S.), Samsung Medical Center; Department of Digital Health (H.J., S.L., K.K., S.W.S.), Samsung Advanced Institute for Health Sciences & Technology, Sungkyunkwan University; Department of Neurology (H.J., H.J.K., J.P.K., S.W.S.), Samsung Medical Center, Sungkyunkwan University School of Medicine; Neuroscience Center (H.J., H.J.K., J.P.K., S.W.S.), Samsung Medical Center; Happymind Clinic (D.L.N.); Biomedical Statistics Center (K.K.), Research Institute for Future Medicine, Samsung Medical Center; and Department of Data Convergence and Future Medicine (K.K.), Sungkyunkwan University School of Medicine, Seoul, Korea. Dr. Jang is currently at the Department of Neurology, Seoul National University Hospital, Korea.
Hee Jin KimFrom the Alzheimer's Disease Convergence Research Center (H.J., S.A., Y.P., S.-J.K., B.K.C., J.H.K., H.J.K., D.L.N., J.P.K., S.W.S.), Samsung Medical Center; Department of Digital Health (H.J., S.L., K.K., S.W.S.), Samsung Advanced Institute for Health Sciences & Technology, Sungkyunkwan University; Department of Neurology (H.J., H.J.K., J.P.K., S.W.S.), Samsung Medical Center, Sungkyunkwan University School of Medicine; Neuroscience Center (H.J., H.J.K., J.P.K., S.W.S.), Samsung Medical Center; Happymind Clinic (D.L.N.); Biomedical Statistics Center (K.K.), Research Institute for Future Medicine, Samsung Medical Center; and Department of Data Convergence and Future Medicine (K.K.), Sungkyunkwan University School of Medicine, Seoul, Korea. Dr. Jang is currently at the Department of Neurology, Seoul National University Hospital, Korea.ORCID 0000-0002-3186-9441
Duk L NaFrom the Alzheimer's Disease Convergence Research Center (H.J., S.A., Y.P., S.-J.K., B.K.C., J.H.K., H.J.K., D.L.N., J.P.K., S.W.S.), Samsung Medical Center; Department of Digital Health (H.J., S.L., K.K., S.W.S.), Samsung Advanced Institute for Health Sciences & Technology, Sungkyunkwan University; Department of Neurology (H.J., H.J.K., J.P.K., S.W.S.), Samsung Medical Center, Sungkyunkwan University School of Medicine; Neuroscience Center (H.J., H.J.K., J.P.K., S.W.S.), Samsung Medical Center; Happymind Clinic (D.L.N.); Biomedical Statistics Center (K.K.), Research Institute for Future Medicine, Samsung Medical Center; and Department of Data Convergence and Future Medicine (K.K.), Sungkyunkwan University School of Medicine, Seoul, Korea. Dr. Jang is currently at the Department of Neurology, Seoul National University Hospital, Korea.
Jun Pyo KimFrom the Alzheimer's Disease Convergence Research Center (H.J., S.A., Y.P., S.-J.K., B.K.C., J.H.K., H.J.K., D.L.N., J.P.K., S.W.S.), Samsung Medical Center; Department of Digital Health (H.J., S.L., K.K., S.W.S.), Samsung Advanced Institute for Health Sciences & Technology, Sungkyunkwan University; Department of Neurology (H.J., H.J.K., J.P.K., S.W.S.), Samsung Medical Center, Sungkyunkwan University School of Medicine; Neuroscience Center (H.J., H.J.K., J.P.K., S.W.S.), Samsung Medical Center; Happymind Clinic (D.L.N.); Biomedical Statistics Center (K.K.), Research Institute for Future Medicine, Samsung Medical Center; and Department of Data Convergence and Future Medicine (K.K.), Sungkyunkwan University School of Medicine, Seoul, Korea. Dr. Jang is currently at the Department of Neurology, Seoul National University Hospital, Korea.
Kyunga KimFrom the Alzheimer's Disease Convergence Research Center (H.J., S.A., Y.P., S.-J.K., B.K.C., J.H.K., H.J.K., D.L.N., J.P.K., S.W.S.), Samsung Medical Center; Department of Digital Health (H.J., S.L., K.K., S.W.S.), Samsung Advanced Institute for Health Sciences & Technology, Sungkyunkwan University; Department of Neurology (H.J., H.J.K., J.P.K., S.W.S.), Samsung Medical Center, Sungkyunkwan University School of Medicine; Neuroscience Center (H.J., H.J.K., J.P.K., S.W.S.), Samsung Medical Center; Happymind Clinic (D.L.N.); Biomedical Statistics Center (K.K.), Research Institute for Future Medicine, Samsung Medical Center; and Department of Data Convergence and Future Medicine (K.K.), Sungkyunkwan University School of Medicine, Seoul, Korea. Dr. Jang is currently at the Department of Neurology, Seoul National University Hospital, Korea.
Sang Won SeoFrom the Alzheimer's Disease Convergence Research Center (H.J., S.A., Y.P., S.-J.K., B.K.C., J.H.K., H.J.K., D.L.N., J.P.K., S.W.S.), Samsung Medical Center; Department of Digital Health (H.J., S.L., K.K., S.W.S.), Samsung Advanced Institute for Health Sciences & Technology, Sungkyunkwan University; Department of Neurology (H.J., H.J.K., J.P.K., S.W.S.), Samsung Medical Center, Sungkyunkwan University School of Medicine; Neuroscience Center (H.J., H.J.K., J.P.K., S.W.S.), Samsung Medical Center; Happymind Clinic (D.L.N.); Biomedical Statistics Center (K.K.), Research Institute for Future Medicine, Samsung Medical Center; and Department of Data Convergence and Future Medicine (K.K.), Sungkyunkwan University School of Medicine, Seoul, Korea. Dr. Jang is currently at the Department of Neurology, Seoul National University Hospital, Korea.
Samsung (South Korea) · KR
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectiveWe aimed to investigate the association between glycemic variability (GV) and neuroimaging markers of white matter hyperintensities (WMH), beta-amyloid (Aβ), brain atrophy, and cognitive impairment.
methodsThis was a retrospective cohort study that included participants without dementia from a memory clinic. They all had Aβ PET, brain MRI, and standardized neuropsychological tests and had fasting glucose (FG) levels tested more than twice during the study period. We defined GV as the intraindividual visit-to-visit variability in FG levels. Multivariable linear regression and logistic regression were used to identify whether GV was associated with the presence of severe WMH and Aβ uptake with DM, mean FG levels, age, sex, hypertension, and presence of
resultsAmong the 688 participants, the mean age was 72.2 years, and the proportion of female participants was 51.9%. Increase in GV was predictive of the presence of severe WMH (coefficient [95% CI] 1.032 [1.012-1.054]; DISCUSSION: Our findings suggest that increased GV is related to vascular and Alzheimer risk factors and neurodegenerative markers, which in turn leads to subsequent cognitive impairment. Furthermore, GV can be considered a potentially modifiable risk factor for dementia prevention.
Indexed as
Central Nervous System DiseasesCognitive DysfunctionDementiaLeukoaraiosisNeurodegenerative DiseasesAgedAmyloid beta-PeptidesAtrophyFemaleHippocampusHumansNeuroimagingRetrospective StudiesAmyloid beta-Peptides
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.